Merck & Co., Inc.: Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (=12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
Opinion granted based on positive results from the Phase 3 KEYNOTE-716 trial If approved, KEYTRUDA would be the first anti-PD-1 immunotherapy treatment option for patients 12 years and older in